Feasibility and therapeutic strategies of vaccines against Porphyromonas gingivalis

References

• Rylev M, Kilian M. Prevalence and distribution of principal periodontal pathogens worldwide. J. Clin. Periodontol.35(8 Suppl.), 346–361 (2008).
   PubMed Web of Science ®Google Scholar
• Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet366(9499), 1809–1820 (2005).
   PubMed Web of Science ®Google Scholar
• Paster BJ, Boches SK, Galvin JL et al. Bacterial diversity in human subgingival plaque. J. Bacteriol.183(12), 3770–3783 (2001).
   PubMed Web of Science ®Google Scholar
• Griffen AL, Becker MR, Lyons SR, Moeschberger ML, Leys EJ. Prevalence of Porphyromonas gingivalis and periodontal health status. J. Clin. Microbiol.36(11), 3239–3242 (1998).
   PubMed Web of Science ®Google Scholar
• Rodenburg JP, van Winkelhoff AJ, Winkel EG, Goene RJ, Abbas F, de Graff J. Occurrence of Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in severe periodontitis in relation to age and treatment history. J. Clin. Periodontol.17(6), 392–399 (1990).
   PubMed Web of Science ®Google Scholar
• Lamont RJ, Jenkinson HF. Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol. Mol. Biol. Rev.62(4), 1244–1263 (1998).
   PubMed Web of Science ®Google Scholar
• Haubek D, Ennibi OK, Poulsen K, Vaeth M, Poulsen S, Kilian M. Risk of aggressive periodontitis in adolescent carriers of the JP2 clone of Aggregatibacter (Actinobacillus) actinomycetemcomitans in Morocco: a prospective longitudinal cohort study. Lancet371(9608), 237–242 (2008).
   PubMed Web of Science ®Google Scholar
• Ogawa T, Tarkowski A, McGhee ML et al. Analysis of human IgG and IgA subclass antibody-secreting cells from localized chronic inflammatory tissue. J. Immunol.142(4), 1150–1158 (1989).
   PubMedGoogle Scholar
• Ogawa T, Kusumoto Y, Hamada S, McGhee JR, Kiyono H. Bacteroides gingivalis-specific serum IgG and IgA subclass antibodies in periodontal diseases. Clin. Exp. Immunol.82(2), 318–325 (1990).
   PubMedGoogle Scholar
• Slots J, Listgarten MA. Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in human periodontal diseases. J. Clin. Periodontol.15(2), 85–93 (1988).
   PubMed Web of Science ®Google Scholar
• Whitney C, Ant J, Moncla B, Johnson B, Page RC, Engel D. Serum immunoglobulin G antibody to Porphyromonas gingivalis in rapidly progressive periodontitis: titer, avidity, and subclass distribution. Infect. Immun.60(6), 2194–2200 (1992).
   PubMedGoogle Scholar
• Okuda K, Kato T, Naito Y et al. Protective efficacy of active and passive immunizations against experimental infection with Bacteroides gingivalis in ligated hamsters. J. Dent. Res.67(5), 807–811 (1988).
   PubMed Web of Science ®Google Scholar
• Chen PB, Neiders ME, Millar SJ, Reynolds HS, Zambon JJ. Effect of immunization on experimental Bacteroides gingivalis infection in a murine model. Infect. Immun.55(10), 2534–2537 (1987).
   PubMedGoogle Scholar
• Genco CA, Kapczynski DR, Cutler CW, Arko RJ, Arnold RR. Influence of immunization on Porphyromonas gingivalis colonization and invasion in the mouse chamber model. Infect. Immun.60(4), 1447–1454 (1992).
   PubMedGoogle Scholar
• Kesavalu L, Ebersole JL, Machen RL, Holt SC. Porphyromonas gingivalis virulence in mice: induction of immunity to bacterial components. Infect. Immun.60(4), 1455–1464 (1992).
   PubMedGoogle Scholar
• Ebersole JL, Brunsvold M, Steffensen B, Wood R, Holt SC. Effects of immunization with Porphyromonas gingivalis and Prevotella intermedia on progression of ligature-induced periodontitis in the nonhuman primate Macaca fascicularis. Infect. Immun.59(10), 3351–3359 (1991).
   PubMedGoogle Scholar
• Persson GR, Engel D, Whitney C et al. Immunization against Porphyromonas gingivalis inhibits progression of experimental periodontitis in nonhuman primates. Infect. Immun.62(3), 1026–1031 (1994).
   PubMed Web of Science ®Google Scholar
• Giardino A, Ebersole JL, Holt SC. Characteristics of systemic antibody responses of nonhuman primates following active immunization with Porphyromonas gingivalis, Prevotella intermedia and Bacteroides fragilis. Oral Microbiol. Immunol.11(2), 79–87 (1996).
   PubMedGoogle Scholar
• Cox SE, Holt SC, Ebersole JL. Characteristics of systemic antibody responses of nonhuman primates to cell envelope and cell wall antigens from periodontal pathogens. Oral Microbiol. Immunol.12(4), 204–211 (1997).
   PubMedGoogle Scholar
• Ebersole JL, Bauman GR, Cox O’Dell SE, Giardino A. Evidence for serum immunoglobulin G (IgG) antibody responses in Macaca fascicularis identified by monoclonal antibodies to human IgG subclasses. Oral Microbiol. Immunol.12(4), 193–203 (1997).
   PubMedGoogle Scholar
• Holt SC, Kesavalu L, Walker S, Genco CA. Virulence factors of Porphyromonas gingivalis. Periodontol. 200020, 168–238 (1999).
   PubMed Web of Science ®Google Scholar
• van Winkelhoff AJ, Appelmelk BJ, Kippuw N, de Graaff J. K-antigens in Porphyromonas gingivalis are associated with virulence. Oral Microbiol. Immunol.8(5), 259–265 (1993).
   PubMedGoogle Scholar
• Laine ML, Appelmelk BJ, van Winkelhoff AJ. Novel polysaccharide capsular serotypes in Porphyromonas gingivalis. J. Periodontal Res.31(4), 278–284 (1996).
   PubMedGoogle Scholar
• Jones C. Vaccine based on the cell surface carbohydrates of pathogenic bacteria. Academia Brasileira de Ciências77(2), 293–324 (2005).
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Aramaki M, Takamatsu N, Koseki T, Kobayashi H, Ishikawa I. Oral administration of Porphyromonas gingivalis fimbriae with cholera toxin induces anti-fimbriae serum IgG, IgM, IgA and salivary IgA antibodies. J. Periodontal Res.34(3), 169–174 (1999).
   PubMedGoogle Scholar
• Wu JJ, Huang DB, Pang KR, Tyring SK. Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations. J. Am. Acad. Dermatol.50(4), 495–528; quiz 529–432 (2004).
   PubMedGoogle Scholar
• d’Empaire G, Baer MT, Gibson FC 3rd. The K1 serotype capsular polysaccharide of Porphyromonas gingivalis elicits chemokine production from murine macrophages that facilitates cell migration. Infect. Immun.74(11), 6236–6243 (2006).
   PubMedGoogle Scholar
• Laine ML, Appelmelk BJ, van Winkelhoff AJ. Prevalence and distribution of six capsular serotypes of Porphyromonas gingivalis in periodontitis patients. J. Dent. Res.76(12), 1840–1844 (1997).
   PubMedGoogle Scholar
• Amano A, Nakagawa I, Okahashi N, Hamada N. Variations of Porphyromonas gingivalis fimbriae in relation to microbial pathogenesis. J. Periodontal Res.39(2), 136–142 (2004).
   PubMed Web of Science ®Google Scholar
• Brunner J, Crielaard W, van Winkelhoff AJ. Analysis of the capsular polysaccharide biosynthesis locus of Porphyromonas gingivalis and development of a K1-specific polymerase chain reaction-based serotyping assay. J. Periodontal Res.43(6), 698–705 (2008).
   PubMedGoogle Scholar
• Gonzalez D, Tzianabos AO, Genco CA, Gibson FC 3rd. Immunization with Porphyromonas gingivalis capsular polysaccharide prevents P. gingivalis-elicited oral bone loss in a murine model. Infect. Immun.71(4), 2283–2287 (2003).
   PubMed Web of Science ®Google Scholar
• Schifferle RE, Chen PB, Davern LB, Aguirre A, Genco RJ, Levine MJ. Modification of experimental Porphyromonas gingivalis murine infection by immunization with a polysaccharide–protein conjugate. Oral Microbiol. Immunol.8(5), 266–271 (1993).
   PubMedGoogle Scholar
• Choi JI, Schifferle RE, Yoshimura F, Kim BW. Capsular polysaccharide–fimbrial protein conjugate vaccine protects against Porphyromonas gingivalis infection in SCID mice reconstituted with human peripheral blood lymphocytes. Infect. Immun.66(1), 391–393 (1998).
   PubMed Web of Science ®Google Scholar
• Martin JE, Pierson TC, Hubka S et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a Phase 1 clinical trial. J. Infect. Dis.196(12), 1732–1740 (2007).
   PubMed Web of Science ®Google Scholar
• Aduse-Opoku J, Slaney JM, Hashim A et al. Identification and characterization of the capsular polysaccharide (K-antigen) locus of Porphyromonas gingivalis. Infect. Immun.74(1), 449–460 (2006).
   PubMedGoogle Scholar
• Sims TJ, Schifferle RE, Ali RW, Skaug N, Page RC. Immunoglobulin G response of periodontitis patients to Porphyromonas gingivalis capsular carbohydrate and lipopolysaccharide antigens. Oral Microbiol. Immunol.16(4), 193–201 (2001).
   PubMedGoogle Scholar
• Sims TJ, Ali RW, Brockman ES, Skaug N, Page RC. Antigenic variation in Porphyromonas gingivalis ribotypes recognized by serum immunoglobulin G of adult periodontitis patients. Oral Microbiol. Immunol.14(2), 73–85 (1999).
   PubMedGoogle Scholar
• Hirschfeld M, Weis JJ, Toshchakov V et al. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun.69(3), 1477–1482 (2001).
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Kaneko T, Kato Y, Golenbock DT, Hara Y. Lipopolysaccharides from periodontopathic bacteria Porphyromonas gingivalis and Capnocytophaga ochracea are antagonists for human Toll-like receptor 4. Infect. Immun.70(1), 218–225 (2002).
   PubMedGoogle Scholar
• Darveau RP, Pham TT, Lemley K et al.Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both Toll-like receptors 2 and 4. Infect. Immun.72(9), 5041–5051 (2004).
   PubMed Web of Science ®Google Scholar
• Kikkert R, Laine ML, Aarden LA, van Winkelhoff AJ. Activation of Toll-like receptors 2 and 4 by Gram-negative periodontal bacteria. Oral Microbiol. Immunol.22(3), 145–151 (2007).
   PubMedGoogle Scholar
• Ogawa T. Chemical structure of lipid A from Porphyromonas (Bacteroides) gingivalis lipopolysaccharide. FEBS Lett.332(1–2), 197–201 (1993).
   PubMed Web of Science ®Google Scholar
• Hajishengallis G, Martin M, Sojar HT et al. Dependence of bacterial protein adhesins on Toll-like receptors for proinflammatory cytokine induction. Clin. Diagn. Lab. Immunol.9(2), 403–411 (2002).
   PubMedGoogle Scholar
• Zhou Q, Desta T, Fenton M, Graves DT, Amar S. Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect. Immun.73(2), 935–943 (2005).
   PubMedGoogle Scholar
• Hajishengallis G, Tapping RI, Harokopakis E et al. Differential interactions of fimbriae and lipopolysaccharide from Porphyromonas gingivalis with the Toll-like receptor 2-centred pattern recognition apparatus. Cell. Microbiol.8(10), 1557–1570 (2006).
   PubMed Web of Science ®Google Scholar
• Gaddis DE, Michalek SM, Katz J. Requirement of TLR4 and CD14 in dendritic cell activation by hemagglutinin B from Porphyromonas gingivalis. Mol. Immunol.46(13), 2493–2504 (2009).
   PubMedGoogle Scholar
• Chen PB, Davern LB, Schifferle R, Zambon JJ. Protective immunization against experimental Bacteroides (Porphyromonas) gingivalis infection. Infect. Immun.58(10), 3394–3400 (1990).
   PubMedGoogle Scholar
• Elkins KL, Stashak PW, Baker PJ. Prior exposure to subimmunogenic amounts of some bacterial lipopolysaccharides induces specific immunological unresponsiveness. Infect. Immun.55(12), 3085–3092 (1987).
   PubMedGoogle Scholar
• de Greeff SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr. Infect. Dis. J.27(3), 218–223 (2008).
   PubMed Web of Science ®Google Scholar
• Yoshimura F, Nishikata M, Suzuki T, Hoover CI, Newbrun E. Characterization of a trypsin-like protease from the bacterium Bacteroides gingivalis isolated from human dental plaque. Arch. Oral Biol.29(7), 559–564 (1984).
   PubMed Web of Science ®Google Scholar
• Hamada N, Sojar HT, Cho MI, Genco RJ. Isolation and characterization of a minor fimbria from Porphyromonas gingivalis. Infect. Immun.64(11), 4788–4794 (1996).
   PubMed Web of Science ®Google Scholar
• Yoshimura F, Takahashi Y, Hibi E, Takasawa T, Kato H, Dickinson DP. Proteins with molecular masses of 50 and 80 kilodaltons encoded by genes downstream from the fimbrilin gene (fimA) are components associated with fimbriae in the oral anaerobe Porphyromonas gingivalis. Infect. Immun.61(12), 5181–5189 (1993).
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Murakami Y, Nagata H, Shizukuishi S, Kawagishi I, Yoshimura F. Involvement of minor components associated with the FimA fimbriae of Porphyromonas gingivalis in adhesive functions. Microbiology153(Pt 6), 1916–1925 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshimura F, Murakami Y, Nishikawa K, Hasegawa Y, Kawaminami S. Surface components of Porphyromonas gingivalis. J. Periodontal Res.44(1), 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Lee JY, Sojar HT, Bedi GS, Genco RJ. Porphyromonas (Bacteroides) gingivalis fimbrillin: size, amino-terminal sequence, and antigenic heterogeneity. Infect. Immun.59(1), 383–389 (1991).
   PubMed Web of Science ®Google Scholar
• Nakagawa I, Amano A, Kimura RK, Nakamura T, Kawabata S, Hamada S. Distribution and molecular characterization of Porphyromonas gingivalis carrying a new type of fimA gene. J. Clin. Microbiol.38(5), 1909–1914 (2000).
   PubMed Web of Science ®Google Scholar
• Nakagawa I, Amano A, Ohara-Nemoto Y et al. Identification of a new variant of fimA gene of Porphyromonas gingivalis and its distribution in adults and disabled populations with periodontitis. J. Periodontal Res.37(6), 425–432 (2002).
   PubMed Web of Science ®Google Scholar
• Amano A, Nakagawa I, Kataoka K, Morisaki I, Hamada S. Distribution of Porphyromonas gingivalis strains with fimA genotypes in periodontitis patients. J. Clin. Microbiol.37(5), 1426–1430 (1999).
   PubMed Web of Science ®Google Scholar
• Kato T, Kawai S, Nakano K et al. Virulence of Porphyromonas gingivalis is altered by substitution of fimbria gene with different genotype. Cell. Microbiol.9(3), 753–765 (2007).
   PubMed Web of Science ®Google Scholar
• Ogawa T, Uchida H, Hamada S. Porphyromonas gingivalis fimbriae and their synthetic peptides induce proinflammatory cytokines in human peripheral blood monocyte cultures. FEMS Microbiol. Lett.116(2), 237–242 (1994).
   PubMedGoogle Scholar
• Harokopakis E, Hajishengallis G. Integrin activation by bacterial fimbriae through a pathway involving CD14, Toll-like receptor 2, and phosphatidylinositol-3-kinase. Eur. J. Immunol.35(4), 1201–1210 (2005).
   PubMed Web of Science ®Google Scholar
• Hajishengallis G, Ratti P, Harokopakis E. Peptide mapping of bacterial fimbrial epitopes interacting with pattern recognition receptors. J. Biol. Chem.280(47), 38902–38913 (2005).
   PubMedGoogle Scholar
• Hajishengallis G, Wang M, Harokopakis E, Triantafilou M, Triantafilou K. Porphyromonas gingivalis fimbriae proactively modulate b2 integrin adhesive activity and promote binding to and internalization by macrophages. Infect. Immun.74(10), 5658–5666 (2006).
   PubMedGoogle Scholar
• Wang M, Shakhatreh MA, James D et al. Fimbrial proteins of Porphyromonas gingivalis mediate in vivo virulence and exploit TLR2 and complement receptor 3 to persist in macrophages. J. Immunol.179(4), 2349–2358 (2007).
   PubMed Web of Science ®Google Scholar
• Evans RT, Klausen B, Sojar HT et al. Immunization with Porphyromonas (Bacteroides) gingivalis fimbriae protects against periodontal destruction. Infect. Immun.60(7), 2926–2935 (1992).
   PubMed Web of Science ®Google Scholar
• Fan Q, Sims T, Sojar H, Genco R, Page RC. Fimbriae of Porphyromonas gingivalis induce opsonic antibodies that significantly enhance phagocytosis and killing by human polymorphonuclear leukocytes. Oral Microbiol. Immunol.16(3), 144–152 (2001).
   PubMedGoogle Scholar
• Yanagita M, Hiroi T, Kitagaki N et al. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J. Immunol.162(6), 3559–3565 (1999).
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Kumada H, Hamada N et al. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit. Oral Microbiol. Immunol.22(6), 374–380 (2007).
   PubMedGoogle Scholar
• Guo H, Wang X, Jiang G, Yang P. Construction of a sIgA-enhancing anti-Porphyromonas gingivalis FimA vaccine and nasal immunization in mice. Immunol. Lett.107(1), 71–75 (2006).
   PubMedGoogle Scholar
• Kawabata S, Terao Y, Fujiwara T, Nakagawa I, Hamada S. Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice. Infect. Immun.67(11), 5863–5868 (1999).
   PubMed Web of Science ®Google Scholar
• Sharma A, Honma K, Evans RT, Hruby DE, Genco RJ. Oral immunization with recombinant Streptococcus gordonii expressing porphyromonas gingivalis FimA domains. Infect. Immun.69(5), 2928–2934 (2001).
   PubMed Web of Science ®Google Scholar
• Yu F, Xu QA, Sun G, Chen W. CTLA4 targeting strategy in DNA vaccination against periodontitis. Med. Hypotheses72(1), 41–42 (2009).
   PubMedGoogle Scholar
• Murakami Y, Imai M, Nakamura H, Yoshimura F. Separation of the outer membrane and identification of major outer membrane proteins from Porphyromonas gingivalis. Eur. J. Oral Sci.110(2), 157–162 (2002).
   PubMedGoogle Scholar
• Nelson KE, Fleischmann RD, DeBoy RT et al. Complete genome sequence of the oral pathogenic Bacterium porphyromonas gingivalis strain W83. J. Bacteriol.185(18), 5591–5601 (2003).
   PubMed Web of Science ®Google Scholar
• Ross BC, Czajkowski L, Vandenberg KL et al. Characterization of two outer membrane protein antigens of Porphyromonas gingivalis that are protective in a murine lesion model. Oral Microbiol. Immunol.19(1), 6–15 (2004).
   PubMedGoogle Scholar
• Shi X, Hanley SA, Faray-Kele MC et al. The rag locus of Porphyromonas gingivalis contributes to virulence in a murine model of soft tissue destruction. Infect. Immun.75(4), 2071–2074 (2007).
   PubMed Web of Science ®Google Scholar
• Hall LM, Fawell SC, Shi X et al. Sequence diversity and antigenic variation at the rag locus of Porphyromonas gingivalis. Infect. Immun.73(7), 4253–4262 (2005).
   PubMed Web of Science ®Google Scholar
• Slakeski N, Dashper SG, Cook P, Poon C, Moore C, Reynolds EC. A Porphyromonas gingivalis genetic locus encoding a heme transport system. Oral Microbiol. Immunol.15(6), 388–392 (2000).
   PubMedGoogle Scholar
• Dashper SG, Hendtlass A, Slakeski N et al. Characterization of a novel outer membrane hemin-binding protein of Porphyromonas gingivalis. J. Bacteriol.182(22), 6456–6462 (2000).
   PubMed Web of Science ®Google Scholar
• Ross BC, Czajkowski L, Hocking D et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine19(30), 4135–4142 (2001).
   PubMed Web of Science ®Google Scholar
• Hamada N, Watanabe K, Tahara T et al. The r40-kDa outer membrane protein human monoclonal antibody protects against Porphyromonas gingivalis-induced bone loss in rats. J. Periodontol.78(5), 933–939 (2007).
   PubMedGoogle Scholar
• Namikoshi J, Otake S, Maeba S, Hayakawa M, Abiko Y, Yamamoto M. Specific antibodies induced by nasally administered 40-kDa outer membrane protein of Porphyromonas gingivalis inhibits coaggregation activity of P. gingivalis. Vaccine22(2), 250–256 (2003).
   PubMed Web of Science ®Google Scholar
• Maeba S, Otake S, Namikoshi J et al. Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis. Vaccine23(19), 2513–2521 (2005).
   PubMed Web of Science ®Google Scholar
• Koizumi Y, Kurita-Ochiai T, Yamamoto M. Transcutaneous immunization with an outer membrane protein of Porphyromonas gingivalis without adjuvant elicits marked antibody responses. Oral Microbiol. Immunol.23(2), 131–138 (2008).
   PubMedGoogle Scholar
• Momoi F, Hashizume T, Kurita-Ochiai T, Yuki Y, Kiyono H, Yamamoto M. Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies. Infect. Immun.76(6), 2777–2784 (2008).
   PubMedGoogle Scholar
• Zhang T, Hashizume T, Kurita-Ochiai T, Yamamoto M. Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem. Biophys. Res. Commun.390(3), 937–941 (2009).
   PubMed Web of Science ®Google Scholar
• Potempa J, Pike R, Travis J. The multiple forms of trypsin-like activity present in various strains of Porphyromonas gingivalis are due to the presence of either Arg-gingipain or Lys-gingipain. Infect. Immun.63(4), 1176–1182 (1995).
   PubMed Web of Science ®Google Scholar
• Curtis MA, Kuramitsu HK, Lantz M et al. Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis. J. Periodontal Res.34(8), 464–472 (1999).
   PubMed Web of Science ®Google Scholar
• Grenier D, Roy S, Chandad F et al. Effect of inactivation of the Arg- and/or Lys-gingipain gene on selected virulence and physiological properties of Porphyromonas gingivalis. Infect. Immun.71(8), 4742–4748 (2003).
   PubMedGoogle Scholar
• Kuboniwa M, Amano A, Shizukuishi S. Hemoglobin-binding protein purified from Porphyromonas gingivalis is identical to lysine-specific cysteine proteinase (Lys-gingipain). Biochem. Biophys. Res. Commun.249(1), 38–43 (1998).
   PubMedGoogle Scholar
• Page RC, Lantz MS, Darveau R et al. Immunization of Macaca fascicularis against experimental periodontitis using a vaccine containing cysteine proteases purified from Porphyromonas gingivalis. Oral Microbiol. Immunol.22(3), 162–168 (2007).
   PubMedGoogle Scholar
• Nakagawa T, Sims T, Fan Q et al. Functional characteristics of antibodies induced by Arg-gingipain (HRgpA) and Lys-gingipain (Kgp) from Porphyromonas gingivalis. Oral Microbiol. Immunol.16(4), 202–211 (2001).
   PubMedGoogle Scholar
• Gibson FC 3rd, Genco CA. Prevention of Porphyromonas gingivalis-induced oral bone loss following immunization with gingipain R1. Infect. Immun.69(12), 7959–7963 (2001).
   PubMed Web of Science ®Google Scholar
• Genco CA, Odusanya BM, Potempa J, Mikolajczyk-Pawlinska J, Travis J. A peptide domain on gingipain R which confers immunity against Porphyromonas gingivalis infection in mice. Infect. Immun.66(9), 4108–4114 (1998).
   PubMed Web of Science ®Google Scholar
• O’Brien-Simpson NM, Black CL, Bhogal PS et al. Serum immunoglobulin G (IgG) and IgG subclass responses to the RgpA–Kgp proteinase–adhesin complex of Porphyromonas gingivalis in adult periodontitis. Infect. Immun.68(5), 2704–2712 (2000).
   PubMedGoogle Scholar
• O’Brien-Simpson NM, Paolini RA, Reynolds EC. RgpA–Kgp peptide-based immunogens provide protection against Porphyromonas gingivalis challenge in a murine lesion model. Infect. Immun.68(7), 4055–4063 (2000).
   PubMed Web of Science ®Google Scholar
• Rajapakse PS, O’Brien-Simpson NM, Slakeski N, Hoffmann B, Reynolds EC. Immunization with the RgpA–Kgp proteinase–adhesin complexes of Porphyromonas gingivalis protects against periodontal bone loss in the rat periodontitis model. Infect. Immun.70(5), 2480–2486 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien-Simpson NM, Pathirana RD, Paolini RA et al. An immune response directed to proteinase and adhesin functional epitopes protects against Porphyromonas gingivalis-induced periodontal bone loss. J. Immunol.175(6), 3980–3989 (2005).
   PubMed Web of Science ®Google Scholar
• Frazer LT, O’Brien-Simpson NM, Slakeski N et al. Vaccination with recombinant adhesins from the RgpA–Kgp proteinase–adhesin complex protects against Porphyromonas gingivalis infection. Vaccine24(42–43), 6542–6554 (2006).
   PubMedGoogle Scholar
• Tam V, O’Brien-Simpson NM, PathiranaRD, Frazer LT, Reynolds EC. Characterization of T cell responses to the RgpA–Kgp proteinase–adhesin complexes of Porphyromonas gingivalis in BALB/c mice. J. Immunol.181(6), 4150–4158 (2008).
   PubMedGoogle Scholar
• Miyachi K, Ishihara K, Kimizuka R, Okuda K. Arg-gingipain A DNA vaccine prevents alveolar bone loss in mice. J. Dent. Res.86(5), 446–450 (2007).
   PubMedGoogle Scholar
• Yonezawa H, Ishihara K, Okuda K. Arg-gingipain a DNA vaccine induces protective immunity against infection by Porphyromonas gingivalis in a murine model. Infect. Immun.69(5), 2858–2864 (2001).
   PubMedGoogle Scholar
• Nakayama K, Kadowaki T, Okamoto K, Yamamoto K. Construction and characterization of arginine-specific cysteine proteinase (Arg-gingipain)-deficient mutants of Porphyromonas gingivalis. Evidence for significant contribution of Arg-gingipain to virulence. J. Biol. Chem.270(40), 23619–23626 (1995).
   PubMed Web of Science ®Google Scholar
• Yonezawa H, Kato T, Kuramitsu HK, Okuda K, Ishihara K. Immunization by Arg-gingipain A DNA vaccine protects mice against an invasive Porphyromonas gingivalis infection through regulation of interferon-γ production. Oral Microbiol. Immunol.20(5), 259–266 (2005).
   PubMedGoogle Scholar
• Kuboniwa M, Amano A, Shizukuishi S, Nakagawa I, Hamada S. Specific antibodies to Porphyromonas gingivalis Lys-gingipain by DNA vaccination inhibit bacterial binding to hemoglobin and protect mice from infection. Infect. Immun.69(5), 2972–2979 (2001).
   PubMed Web of Science ®Google Scholar
• Han N, Whitlock J, Progulske-Fox A. The hemagglutinin gene A (hagA) of Porphyromonas gingivalis 381 contains four large, contiguous, direct repeats. Infect. Immun.64(10), 4000–4007 (1996).
   PubMed Web of Science ®Google Scholar
• Katz J, Black KP, Michalek SM. Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model. Infect. Immun.67(9), 4352–4359 (1999).
   PubMed Web of Science ®Google Scholar
• Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. J. Clin. Periodontol.25(2), 134–144 (1998).
   PubMed Web of Science ®Google Scholar
• Rhemrev GE, Timmerman MF, Veldkamp I, Van Winkelhoff AJ, Van der Velden U. Immediate effect of instrumentation on the subgingival microflora in deep inflamed pockets under strict plaque control. J. Clin. Periodontol.33(1), 42–48 (2006).
   PubMed Web of Science ®Google Scholar
• Fujise O, Hamachi T, Inoue K, Miura M, Maeda K. Microbiological markers for prediction and assessment of treatment outcome following non-surgical periodontal therapy. J. Periodontol.73(11), 1253–1259 (2002).
   PubMedGoogle Scholar
• Magnusson I, Lindhe J, Yoneyama T, Liljenberg B. Recolonization of a subgingival microbiota following scaling in deep pockets. J. Clin. Periodontol.11(3), 193–207 (1984).
   PubMed Web of Science ®Google Scholar
• van Winkelhoff AJ, Loos BG, van der Reijden WA, van der Velden U. Porphyromonas gingivalis, Bacteroides forsythus and other putative periodontal pathogens in subjects with and without periodontal destruction. J. Clin. Periodontol.29(11), 1023–1028 (2002).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine21(Suppl. 2), S89–S95 (2003).
   PubMed Web of Science ®Google Scholar
• Yang QB, Martin M, Michalek SM, Katz J. Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis. Infect. Immun.70(7), 3557–3565 (2002).
   PubMed Web of Science ®Google Scholar
• Dusek DM, Progulske-Fox A, Brown TA. Systemic and mucosal immune responses in mice orally immunized with avirulent Salmonella typhimurium expressing a cloned Porphyromonas gingivalis hemagglutinin. Infect. Immun.62(5), 1652–1657 (1994).
   PubMed Web of Science ®Google Scholar
• Isoda R, Simanski SP, Pathangey L, Stone AE, Brown TA. Expression of a Porphyromonas gingivalis hemagglutinin on the surface of a Salmonella vaccine vector. Vaccine25(1), 117–126 (2007).
   PubMed Web of Science ®Google Scholar
• Shibata Y, Hosogi Y, Hayakawa M, Hori N, Kamada M, Abiko Y. Construction of novel human monoclonal antibodies neutralizing Porphyromonas gingivalis hemagglutination activity using transgenic mice expressing human Ig loci. Vaccine23(29), 3850–3856 (2005).
   PubMed Web of Science ®Google Scholar